Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Category | Sectoral / Thematic | Sectoral / Thematic |
| Plan | Regular | Regular |
| Fund house | Nippon India | Axis |
| NAV | ₹591.2429 | ₹21.0800 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | 20.6 years | 6.8 years |
| Expense ratio | 1.8% | 2.6% |
| Stars | ★★★★★ | ★★★★★ |
| Growth Score | 78.10 | 28.20 |
Returns
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| 1 month | +11.32% | +6.63% |
| 3 months | +3.52% | −0.38% |
| 6 months | +8.09% | +3.89% |
| YTD | +16.05% | −3.88% |
| 1 year | +14.27% | −3.92% |
| 3 years (CAGR) | +16.91% | +7.49% |
| 5 years (CAGR) | +14.37% | +4.29% |
| 10 years (CAGR) | +15.58% | — |
| Since launch | +17.64% | +11.50% |
Risk
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Volatility | 14.1% | 14.0% |
| Downside volatility | 9.1% | 10.4% |
| Sharpe | 0.74 | 0.07 |
| Sortino | 1.15 | 0.10 |
| Calmar | 1.14 | 0.40 |
| Return / risk | 1.20 | 0.53 |
| Deepest fall | −47.36% | −25.09% |
| Days to recover | 301 | 531 |
| Below its high | +0.00% | −9.45% |
Against benchmark
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Alpha | −2.75% | — |
| Beta | 0.89 | — |
| R² | 89.5% | — |
| Up capture | 83.5% | — |
| Down capture | 91.2% | — |
| Tracking error | 4.8% | — |
| Information ratio | −0.88 | — |
| Treynor | 0.11 | — |
Consistency
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Best 1-year | +175.79% | +67.94% |
| Middle 1-year | +13.84% | +8.07% |
| Worst 1-year | −36.67% | −17.67% |
| 1-year periods with a loss | 23.4% | 31.3% |
| Middle 3-year | +20.93% | +11.69% |
| Positive months | 63.9% | 63.9% |
| Best day | +3.40% | +3.73% |
| Worst day | −3.21% | −3.59% |
| Worst 5% day | −1.38% | −1.23% |
| Positive days | 53.7% | 51.4% |
| NAVs a year | 247 | 251 |
SIP of ₹10,000 a month
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| 5-year XIRR | +17.18% | +6.26% |
| 5-year value | ₹9,29,284 | ₹7,05,168 |
| 3-year XIRR | +13.26% | +2.23% |
| 1-year XIRR | +21.05% | +1.90% |
Holdings overlap i
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Nippon India Pharma Fund | — | 8% |
| Axis ESG Integration Strategy Fund | 8% | — |
Share of money in the same stocks, by weight. Above 50% means much of one fund repeats the other.
Held by all of them
| Stock | Nippon India Pharma Fund | Axis ESG Integration Strategy Fund |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.55% | 2.77% |
| IPCA Laboratories Limited | 2.90% | 1.35% |
| Anthem Biosciences Limited | 1.30% | 1.67% |
| Biocon Limited | 0.97% | 2.29% |
| Alkem Laboratories Limited | 1.82% | 0.73% |
| Gland Pharma Limited | 2.73% | 0.39% |
Sectors and company size
| Nippon India Pharma Fund | Axis ESG Integration Strategy Fund | |
|---|---|---|
| Large companies | 29.6% | 49.8% |
| Mid companies | 40.8% | 13.1% |
| Small companies | 28.7% | 21.2% |
| Top 10 holdings | 57.2% | 49.5% |
| Largest sector | Pharmaceuticals & Biotechnology 75% | Finance 13% |